InvestorsObserver
×
News Home

Should You Add Cyclerion Therapeutics Inc (CYCN) Stock to Your Portfolio Wednesday?

Wednesday, August 16, 2023 10:31 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Add Cyclerion Therapeutics Inc (CYCN) Stock to Your Portfolio Wednesday?

Cyclerion Therapeutics Inc (CYCN) is near the bottom in its sector according to InvestorsObserver. CYCN gets an overall rating of 4. That means it scores higher than 4% of stocks. Cyclerion Therapeutics Inc gets a 11 rank in the Healthcare sector. Healthcare is number 5 out of 11 sectors.

Overall Score - 4
CYCN has an Overall Score of 4. Find out what this means to you and get the rest of the rankings on CYCN!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 4 means the stock is more attractive than 4 percent of stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Cyclerion Therapeutics Inc Stock Today?

Cyclerion Therapeutics Inc (CYCN) stock is trading at $3.90 as of 9:30 AM on Wednesday, Aug 16, an increase of $0.14, or 3.77% from the previous closing price of $3.76. The stock has traded between $3.90 and $3.90 so far today. Volume today is less active than usual. So far 1,579 shares have traded compared to average volume of 8,592 shares. Click Here to get the full Stock Report for Cyclerion Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App